Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Sanji Kanaoka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Urology, Graduate School of Medicine, Ch…. Hauptthemen laut MEDLINE: Chromatin, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Chiba University, Takeda Science Foundation, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Epigenetic modifiers are upregulated during the process of prostate cancer, acquiring resistance to castration therapy and becoming lethal metastatic castration-resistant prostate cancer (CRPC). However, the relationship between regulation of histone modifications and chromatin structure in CRPC has yet not fully been validated. Here, we reanalyzed publicly available clinical transcriptome and clinical outcome data and identified NSD2, a histone methyltransferase that catalyzes H3K36me2, as an epigenetic modifier that was upregulated in CRPC and whose increased expression in prostate cancer correlated with higher recurrence rate. We performed ChIP-seq, RNA-seq, and Hi-C to conduct comprehensive epigenomic and transcriptomic analyses to identify epigenetic reprogramming in CRPC. In regions where H3K36me2 was increased, H3K27me3 was decreased, and the compartment was shifted from inactive to active. In these regions, 68 aberrantly activated genes were identified as candidate downstream genes of NSD2 in CRPC. Among these genes, we identified KIF18A as critical for CRPC growth. Under NSD2 upregulation in CRPC, epigenetic alteration with H3K36me2-gain and H3K27me3-loss occurs accompanying with an inactive-to-active compartment shift, suggesting that histone modification and chromatin structure cooperatively change prostate carcinogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan; Health and Disease Omics Center, Chiba University, Chiba, Japan.
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan; Health and Disease Omics Center, Chiba University, Chiba, Japan. Electronic address: kaneda@chiba-u.jp.
Förderung
- Chiba University
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
Zitieren
APA
Kanaoka, S., Okabe, A., Kanesaka, M., Rahmutulla, B., Fukuyo, M., Seki, M., Hoshii, T., Sato, H., Imamura, Y., Sakamoto, S., Ichikawa, T., & Kaneda, A. (2024). Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216815
Vancouver
Kanaoka S, Okabe A, Kanesaka M, Rahmutulla B, Fukuyo M, Seki M, et al. Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216815
BibTeX
@article{Kanaoka2024,
author = {Kanaoka, Sanji and Okabe, Atsushi and Kanesaka, Manato and Rahmutulla, Bahityar and Fukuyo, Masaki and Seki, Motoaki and Hoshii, Takayuki and Sato, Hiroaki and Imamura, Yusuke and Sakamoto, Shinichi and Ichikawa, Tomohiko and Kaneda, Atsushi},
title = {Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216815}
}
EUVIMED